MEDALIST Trial Background and Rationale

Similar documents
CheckMate 153: Randomized Results of Continuous vs 1-Year Fixed-Duration Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer

The RUTHERFORD-2 trial in heterozygous FH: Results and implications

SYNOPSIS Final Abbreviated Clinical Study Report for Study CA ABBREVIATED REPORT

Efficacy of Pembrolizumab in Patients With Advanced Melanoma With Stable Brain Metastases at Baseline: A Pooled Retrospective Analysis

Efficacy of Sonidegib in Patients With Metastatic BCC (mbcc)

Safety and Tolerability of Subcutaneous Sarilumab and Intravenous Tocilizumab in Patients With RA

Clinical Study Report Synopsis Drug Substance Naloxegol Study Code D3820C00018 Edition Number 1 Date 01 February 2013 EudraCT Number

Introduction. These patients benefit less from conventional chemotherapy than patients identified as MMR proficient or microsatellite stable 3-5

A review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital

Supplementary Online Content

Presented at the 75 th Annual Meeting of the American Academy of Dermatology, Orlando, FL, March 3-7, 2017 METHODS INTRODUCTION OBJECTIVE

ClinicalTrials.gov Identifier: NCT

Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis

Start ORKAMBI today. INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION. Sydney Age 4

R Martino 1, P Romero 1, M Subirá 1, M Bellido 1, A Altés 1, A Sureda 1, S Brunet 1, I Badell 2, J Cubells 2 and J Sierra 1

ASH 2018 MEDALIST & BELIEVE Phase 3 Trial Presentation Highlights. December 3, 2018

Abstract. Background. Aim. Patients and Methods. Patients. Study Design

Gemmis Injection 38 mg/ml

Chilblains (pernio, perniosis) are cold-induced, painful or itching

Emerging Options for Thromboprophylaxis After Orthopedic Surgery: A Review of Clinical Data

IMpower133: Primary PFS, OS, and safety in a Ph1/3 study of 1L atezolizumab + carboplatin + etoposide in extensive-stage SCLC

Original Article. T Akter 1, N Islam 2, MA Hoque 3, S Khanam 4, HA khan 5, BK Saha 6. Abstract:

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. doi: /ajg.2012.

Results. Table 1: Demographic and Baseline Characteristics, Open-Label Safety Population Prior Double-Blind OC/APAP ER (n=77)

Impact of Pharmacist Intervention on Diabetes Patients in an Ambulatory Setting

Reference Slide Deck. Abstract 553 Abstract 554 Abstract 560

Bright Futures Medical Screening Reference Table 2 to 5 Day (First Week) Visit

Symptom Management and Supportive Care

PROVEN ANTICOCCIDIAL IN NEW FORMULATION

A nemia of chronic renal failure is a well-established entity, and depending on the primary renal disease, may vary in its severity ( 1 ).

CheckMate-142 Study Design

Management of Relapsed/Refractory Follicular Lymphoma

DOSAGE FORMS AND STRENGTHS HIGHLIGHTS OF PRESCRIBING INFORMATION

Sponsor / Company: Sanofi Drug substance(s): AVE0005 (aflibercept)

A cross-sectional and follow-up study of leukopenia in tuberculosis patients: prevalence, risk factors and impact of anti-tuberculosis

Antiviral Therapy 2015; 20: (doi: /IMP2920)

See 17 for PATIENT COUNSELING INFORMATION and FDAapproved patient labeling. Revised: 6/2016 FULL PRESCRIBING INFORMATION: CONTENTS*

58 % 50 % REDUCTION IN RISK OF OVERT HE RECURRENCE 1

Short-term therapy with lasting relief 2

See 17 for PATIENT COUNSELING INFORMATION. Revised: 09/2017 FULL PRESCRIBING INFORMATION: CONTENTS*

Antiviral Therapy 2015; 20: (doi: /IMP2874)

Treatment of low risk MDS

EVALUATION OF DIFFERENT COPPER SOURCES AS A GROWTH PROMOTER IN SWINE FINISHING DIETS 1

Adverse Events Grading Card

CASE REPORT. Abstract. Introduction

All- Oral 12- Week Combina3on Treatment With Daclatasvir and Sofosbuvir in Pa3ents Infected With HCV Genotype 3: ALLY- 3 Phase 3 Study

Metabolic Syndrome and Health-related Quality of Life in Obese Individuals Seeking Weight Reduction

Risks for All-Cause Mortality: Stratified by Age, Estimated Glomerular Filtration Rate and Albuminuria

See 17 for PATIENT COUNSELING INFORMATION. Revised: 02/2011 FULL PRESCRIBING INFORMATION: CONTENTS*

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors

Metformin and breast cancer stage at diagnosis: a population-based study

PNEUMOVAX 23 is recommended by the CDC for all your appropriate adult patients at increased risk for pneumococcal disease 1,2 :

Comparative Safety of Filgrastim versus Sargramostim in Patients Receiving Myelosuppressive Chemotherapy

Body mass index, waist-to-hip ratio, and metabolic syndrome as predictors of middle-aged men's health

HIGHLIGHTS OF PRESCRIBING INFORMATION

See 17 for PATIENT COUNSELING INFORMATION and FDAapproved

Olanzapine for the prophylaxis and rescue of chemotherapyinduced nausea and vomiting (CINV): a retrospective study

Y. Yazici 1, D. Moniz Reed 2, C. Klem 2, L. Rosenblatt 2, G. Wu 2, J.M. Kremer 3

ULTOMIRIS is administered once every 8 weeks a

In the treatment of cardiovascular disease (CVD), national

Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial

Assessment of Depression in Multiple Sclerosis. Validity of Including Somatic Items on the Beck Depression Inventory II

A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation

Original Article. Diabetes Metab J 2011;35:26-33 doi: /dmj pissn eissn

Patient-Controlled Transdermal Fentanyl Versus Intravenous Morphine Pump After Spine Surgery

PROFILE OF A PATIENT WITH mbc with visceral metastases

FULL PRESCRIBING INFORMATION

Increased Relative Mortality in Women With Severe Oxygen-Dependent COPD

Opioid Use and Survival at the End of Life: A Survey of a Hospice Population

Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi s sarcoma

See 17 for PATIENT COUNSELING INFORMATION and FDAapproved. Revised: 01/2019

Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients ( )

Effect on Glycemic, Blood Pressure, and Lipid Control according to Education Types

Original Article. Breast Care 2016;11: DOI: /

Weight-Based Dosage Regimen: (2.1) Body Weight Range (kg) Loading Dose (mg) Maintenance Dose (mg) greater or equal to 40 to less than 60 2,400 3,000

The incidence of melanoma, the most serious

Addendum to the Evidence Review Group Report on Aripiprazole for the treatment of schizophrenia in adolescents (aged years)

Clinical Study. Oncology 2006;71:32 39 DOI: /

key words: bortezomib, multiple myeloma, retrospective analysis, treatment outcomes, subcutaneous, intravenous

PRACTICE GUIDELINE SERIES

Revised: 6/2018 History of severe hypersensitivity reaction to pemetrexed. (4)

Mortality of patients with multiple sclerosis: a cohort study in UK primary care

Clinical statistics analysis on the characteristics of pneumoconiosis of Chinese miner population

THE natural course of sciatica 22,17,23 is favourable in most

Mecadox. Improves pig performance in a wide range of health and growing conditions. (Carbadox) Talk With a Phibro Expert:

Multicenter Randomized Phase 2 Clinical Trial of a Recombinant Human Endostatin Adenovirus in Patients with Advanced Head and Neck Carcinoma

Esophageal carcinoma is the eighth most common cancer

Bioactive milk components to secure growth and gut development in preterm pigs ESTER ARÉVALO SUREDA PIGUTNET FA1401 STSM

3.3 Verotoxigenic E. coli

Target: 10 mg/day within several days Schizophrenia in adolescents (2.1)

Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation

Therapeutic Angiogenesis With Intramuscular NV1FGF Improves Amputation-free Survival in Patients With Critical Limb Ischemia

Larry Alphs 1*, Cynthia A Bossie 1, Jennifer K Sliwa 1, Yi-Wen Ma 2 and Norris Turner 1. Abstract

Immune-Mediated Adverse Reactions Management Guide

Clinical Evidence for Second- and Third-Line Treatment Options in Advanced Non-Small Cell Lung Cancer

HERCEPTIN (trastuzumab) Intravenous Infusion Initial U.S. Approval: 1998

Treatment of leukemia with partially matched related bone marrow transplantation

of comorbid conditions, interventions Diagnosis and treatment, treatment reduction of risk factors for CVD to slow disease progression,

TR Spitzer 1, CJ Friedman 2, W Bushnell 2, SR Frankel 3, J Raschko 4. Summary:

Epilepsy & Behavior. Ketogenic diet treatment in adults with refractory epilepsy

Transcription:

The MEDALIST Tril: Results of Phse 3, Rndomized, Double-Blind, Plcebo-Controlled Study of to Tret Ptients With Very Low-, Low-, or Intermedite-Risk Myelodysplstic Syndromes (MDS) Associted Anemi With Ring Sideroblsts (RS) Who Require Red Blood Cell (RBC) Trnsfusions Pierre Fenux, Uwe Pltzbecker, Ghulm J. Mufti, Guillermo Grci-Mnero, Ren Buckstein, Vleri Sntini, Mrí Díez-Cmpelo, Crlo Finelli, Mrio Czzol, Osmn Ilhn, Mikkel A. Sekeres, José F. Flntes, Betriz Arrizblg, Flvi Slvi, Vlentin Gii, Presh Vys, Dvid Bowen, Dominik Selleslg, Amy E. DeZern, Joseph G. Jurcic, Ulrich Germing, Kthrin S. Götze, Bruno Quesnel, Odile Beyne-Ruzy, Thoms Cluzeu, Mri Teres Voso, Dominiek Mzure, Edo Velleng, Peter L. Greenberg, Ev Hellström-Lindberg, Amer M. Zeidn, Abderrhmne Ldem, Aziz Benzohr, Jennie Zhng, Anit Rmpersd, Peter G. Linde, Mtthew L. Shermn, Rmi S. Komrokji, Aln F. List

Bckground nd Rtionle Ptients with lower-risk (LR) trnsfusion-dependent MDS hve poorer prognosis, with greter risk of progression to AML nd inferior overll survivl compred with ptients with trnsfusion-independent MDS RBC trnsfusion-dependent LR, non-del(5q) MDS ptients hve trnsient response to ESAs, with n ttendnt risk of iron overlod nd secondry orgn complictions Few tretment options exist for the lrge number of ptients with LR MDS who re either refrctory to or become unresponsive to ESAs 1 IPSS-R-defined criteri. AML, cute myeloid leukemi; ESA, erythropoiesis-stimulting gent; IPSS-R, revised Interntionl Prognostic Scoring System; MDS, myelodysplstic syndromes; RBC, red blood cell. 1. Fenux P, nd Adès L. Blood. 2013;121:4280-4286.

is n investigtionl first-in-clss erythroid mturtion gent tht neutrlizes select TGF-β superfmily lignds to inhibit berrnt Smd2/3 signling nd enhnce lte-stge erythropoiesis in MDS models 1 In phse 2 study in LR, non-del(5q) MDS, lusptercept yielded high frequency of trnsfusion reduction or RBC-TI in ptients with MDS-RS vs other subtypes 2 ActRIIB / IgG1 Fc recombinnt fusion protein Modified extrcellulr domin of ActRIIB Humn IgG1 Fc domin TGF-β superfmily lignd Cytoplsm Nucleus Erythroid mturtion ActRIIB, humn ctivin receptor type IIB; IgG1 Fc, immunoglobulin G1 frgment crystllizble; RBC-TI, red blood cell trnsfusion independence; RS, ring sideroblsts; TGF-β, trnsforming growth fctor bet. ActRIIB P Smd2/3 Complex 1. Surgni RN, et l. Nt Med. 2014;20:408-414; 2. Pltzbecker U, et. A. Lncet Oncol. 2017; 18:1338.

Study Design A Rndomized, Double-Blind, Plcebo-Controlled, Phse 3 Study Ptient Popultion MDS-RS (WHO): 15% RS or 5% with SF3B1 muttion < 5% blsts in bone mrrow No del(5q) MDS IPSS-R Very Low-, Low-, or Intermedite-risk Prior ESA response Refrctory, intolernt ESA nive: EPO > 200 U/L Averge RBC trnsfusion burden 2 units/8 weeks No prior tretment with disese-modifying gents (e.g. imids, HMAs) Rndomize 2:1 1.0 mg/kg (s.c.) every 21 dys n = 153 Dose titrted up to mximum of 1.75 mg/kg Plcebo (s.c.) every 21 dys n = 76 Disese & Response Assessment week 24 & every 6 months Tretment discontinued for lck of clinicl benefit or disese progression per IWG criteri; no crossover llowed Subjects followed 3 yers post finl dose for AML progression, subsequent MDS tretment nd overll survivl Dt cutoff: My 8, 2018 Includes lst subject rndomized + 48 weeks. EPO, erythropoietin; HMA, hypomethylting gent; imid, immunomodultory drug; IWG, Interntionl Working Group; s.c., subcutneously; SF3B1, splicing fctor 3b subunit 1; WHO, World Helth Orgniztion.

Study Design (cont.) Ptients were rndomized between Mrch 2016 nd June 2017 t 65 sites in Belgium, Cnd, Frnce, Germny, Itly, the Netherlnds, Spin, Sweden, Turkey, UK, nd USA

Study Endpoints Primry endpoint: Red blood cell trnsfusion independence 8 weeks (weeks 1 24) Key secondry endpoint: Red blood cell trnsfusion independence 12 weeks (weeks 1 24 nd weeks 1 48) Additionl secondry endpoints: HI-E (IWG 2006 criteri 1 ) for ny consecutive 56-dy period Reduction in red blood cell trnsfusion burden 4 RBC units/8 weeks or Men Hb increse of 1.5 g/dl/8 weeks b Durtion of response Hb chnge from bseline In ptients with bseline RBC trnsfusion burden 4 units/8 weeks. b In ptients with bseline RBC trnsfusion burden < 4 units/8 weeks. Hb, hemoglobin; HI-E, hemtologicl improvement erythroid. 1. Cheson BD, et l. Blood. 2006;108:419-425.

Demogrphics nd Bseline Disese Chrcteristics Chrcteristic (n = 153) Plcebo (n = 76) Age, medin (rnge), yers 71 (40 95) 72 (26 91) Mle, n (%) 94 (61.4) 50 (65.8) Time since originl MDS dignosis, medin (rnge), months 44.0 (3 421) 36.1 (4 193) WHO clssifiction RCMD-RS, n (%) 145 (94.8) 74 (97.4) RBC trnsfusion burden, medin (rnge), units/8 weeks 5 (1 15) 5 (2 20) 6 units/8 weeks, n (%) 66 (43.1) 33 (43.4) < 6 units/8 weeks, n (%) 87 (56.9) 43 (56.6) Pre-trnsfusion Hb, medin (rnge), g/dl 7.6 (6 10) 7.6 (5 9) IPSS-R risk ctegory b Very Low, Low, n (%) 127 (83.0) 63 (82.9) Intermedite, n (%) 25 (16.3) 13 (17.1) SF3B1 muttion, n (%) 141 (92.2) 65 (85.5) c Serum EPO < 200 U/L, n (%) 88 (57.5) c 50 (65.8) 200 U/L, n (%) 64 (41.8) c 26 (34.2) In the 16 weeks prior to rndomiztion. b 1 (0.7%) ptient in the lusptercept rm ws clssified s IPSS-R High-risk. c Dt were missing for 1 ptient. RCMD-RS, refrctory cytopeni with multilinege dysplsi with RS.

Tretment Exposure Prmeter (n = 153) Plcebo (n = 76) Tretment durtion, medin (rnge), weeks 49 (6 114) 24 (7 89) Completed 24 weeks of tretment (primry phse), n (%) 128 (83.7) 68 (89.5) Completed 48 weeks of tretment, n (%) 78 (51.0) 12 (15.8) Number of doses received, medin (rnge) 16 (2 37) 8 (3 30) Mximum dose escltion, n (%) 1.0 mg/kg 35 (22.9) 5 (6.6) 1.33 mg/kg 28 (18.3) 8 (10.5) 1.75 mg/kg 90 (58.8) 63 (82.9) Ptients remining on tretment, n (%) 70 (45.8) 6 (7.9) Ptients discontinued from tretment, n (%) 83 (54.2) 70 (92.1) Lck of benefit 51 (33.3) 50 (65.8) Ptient withdrwl 14 (9.2) 10 (13.2) AE 10 (6.5) 4 (5.3) Disese progression 3 (2.0) 2 (2.6) Other 5 (3.3) 4 (5.3) Dose my be titrted up to mximum of 1.75 mg/kg. AE, dverse event.

Primry Endpoint: Red Blood Cell Trnsfusion Independence 8 Weeks RBC-TI 8 weeks (n = 153) Plcebo (n = 76) Weeks 1 24, n (%) 58 (37.9) 10 (13.2) 95% CI 30.2 46.1 6.5 22.9 P vlue < 0.0001 Cochrn Mntel Henszel test strtified for verge bseline RBC trnsfusion requirement ( 6 units vs < 6 units of RBCs/8 weeks) nd bseline IPSS-R score (Very Low or Low vs Intermedite). CI, confidence intervl.

Primry Endpoint: Subgroup Anlysis, n (%) Plcebo, n (%) OR (95% CI) P Vlue Overll 58/153 (37.9) 10/76 (13.2) 5.06 (2.28 11.3) < 0.0001 Averge bseline RBC trnsfusion requirement 6 units/8 weeks 6/66 (9.1) 1/33 (3.0) 3.20 (0.37 27.7) 0.2699 < 6 units/8 weeks 52/87 (59.8) 9/43 (20.9) 5.61 (2.40 13.1) < 0.0001 4 to < 6 units/8 weeks 15/41 (36.6) 1/23 (4.3) 12.7 (1.55 104) 0.0046 < 4 units/8 weeks 37/46 (80.4) 8/20 (40.0) 6.17 (1.95 19.5) 0.0013 Bseline serum EPO (U/L) < 100 23/51 (45.1) 7/31 (22.6) 2.82 (1.03 7.71) 0.0413 100 to < 200 14/37 (37.8) 2/19 (10.5) 5.17 (1.04 25.9) 0.0338 200 500 17/43 (39.5) 1/15 (6.7) 9.15 (1.10 76.2) 0.0188 Age group 64 yers 17/29 (58.6) 3/16 (18.8) 6.14 (1.43 26.3) 0.0108 65 74 yers 23/72 (31.9) 4/29 (13.8) 2.93 (0.91 9.41) 0.0635 75 yers 18/52 (34.6) 3/31 (9.7) 4.94 (1.32 18.5) 0.0120 Gender Mle 32/94 (34.0) 4/50 (8.0) 5.94 (1.96 18.0) 0.0006 Femle 26/59 (44.1) 6/26 (23.1) 2.63 (0.92 7.48) 0.0673 Time since initil dignosis t bseline 2 yers 14/40 (35.0) 3/19 (15.8) 2.87 (0.71 11.6) 0.1312 > 2 5 yers 30/62 (48.4) 4/34 (11.8) 7.03 (2.21 22.3) 0.0004 > 5 yers 14/51 (27.5) 3/23 (13.0) 2.52 (0.65 9.83) 0.1756 Bseline IPSS-R risk Very Low or Low 48/127 (37.8) 9/63 (14.3) 3.65 (1.65 8.05) 0.0009 Intermedite 10/25 (40.0) 1/13 (7.7) 8.00 (0.89 71.6) 0.0398 Bseline pltelet count < 100 10 9 /L 2/8 (25.0) 1/6 (16.7) 1.67 (0.11 24.3) 0.7171 100 400 10 9 /L 42/128 (32.8) 8/61 (13.1) 3.24 (1.41 7.42) 0.0042 > 400 10 9 /L 14/17 (82.4) 1/9 (11.1) 37.3 (3.31 422) 0.0006 OR, odds rtio. 0 0.1 0.25 0.5 2 10 20 100 1,500 Fvors plcebo Fvors lusptercept

Key Secondry Endpoint: Red Blood Cell Trnsfusion Independence 12 Weeks RBC-TI 12 Weeks (n = 153) Plcebo (n = 76) Weeks 1 24, n (%) 43 (28.1) 6 (7.9) 95% CI 21.14 35.93 2.95 16.40 P vlue 0.0002 Weeks 1 48, n (%) 51 (33.3) 9 (11.8) 95% CI 25.93 41.40 5.56 21.29 P vlue 0.0003 Cochrn Mntel Henszel test strtified for verge bseline RBC trnsfusion requirement ( 6 units vs < 6 units of RBCs/8 weeks) nd bseline IPSS-R score (Very Low or Low vs Intermedite).

Probbility of Mintining RBC-TI MEDALIST Tril Durtion of RBC-TI Response in Primry Endpoint Responders 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0 Medin durtion (weeks) (95% CI): 30.6 (20.6 40.6) vs 13.6 (9.1 54.9) Durtion of RBC-TI (week) Plcebo Censored 0 10 20 30 40 50 60 70 80 90 100 110 120 Number of ptients 58 49 37 29 22 18 10 6 3 2 1 1 0 Plcebo 10 9 3 2 2 2 0 During indicted tretment period. Ptients who mintined RBC-TI t the time of nlysis re censored.

Secondry Endpoint: Erythroid Response (HI-E) (n = 153) Plcebo (n = 76) Achieved HI-E (weeks 1 24), n (%) 81 (52.9) 9 (11.8) Reduction of 4 RBC units/8 weeks (bseline trnsfusion burden 4 units/8 weeks) 52/107 (48.6) 8/56 (14.3) Hb increse of 1.5 g/dl (bseline trnsfusion burden < 4 units/8 weeks) 29/46 (63.0) 1/20 (5.0) 95% CI 44.72 61.05 5.56 21.29 P vlue b < 0.0001 Achieved HI-E (weeks 1 48), n (%) 90 (58.8) 13 (17.1) Reduction of 4 RBC units/8 weeks (bseline RBC trnsfusion burden 4 units/8 weeks) 58/107 (54.2) 12/56 (21.4) Hb increse of 1.5 g/dl (bseline RBC trnsfusion burden < 4 units/8 weeks) 32/46 (69.6) 1/20 (5.0) 95% CI 50.59 66.71 9.43 27.47 P vlue b < 0.0001 Defined s the proportion of ptients meeting the HI-E criteri per IWG 2006 criteri (Cheson et l. 2006) sustined over consecutive 56-dy period during the indicted tretment period. b compred with plcebo, Cochrn Mntel Henszel test.

Hb Men Chnge (± SE) From Bseline (g/dl) MEDALIST Tril Chnge in Hemoglobin Concentrtion 3 Responder receiving lusptercept Non-responder receiving lusptercept Plcebo 2 1 0-1 11/5/2018 Bseline 1 211/26/2018 3 12/17/2018 6 1/7/2019 9 1/28/2019 12 13 2/18/2019 15 3/11/2019 18 4/1/2019 21 4/22/2019 24 Anlysis Week Visit Medin pek hemoglobin increse in lusptercept responders: 2.55 g/dl (1 4.1 g/dl) Number of ptients Responder 24 36 55 53 52 50 42 47 50 42 45 153 Non-responder 33 51 61 52 60 53 34 45 56 48 35 Plcebo 76 32 36 41 47 44 52 29 44 47 44 32 LS men difference (95% CI) for lusptercept responders versus plcebo: 1.08 (0.84, 1.31), P < 0.0001. Only ptients with RBC-TI 8 weeks during weeks 1 24 re included. Hb mesurement ws excluded within 14 dys fter RBC trnsfusion unless within 3 dys prior to nother RBC trnsfusion. Men nd SE were not clculted if the number of ptients ws < 8 in the lusptercept non-responder group or < 4 in the plcebo group. SE, stndrd error.

Sfety Summry (n = 153) Plcebo (n = 76) Ptients with 1 TEAE, n (%) 150 (98.0) 70 (92.1) Ptients with 1 serious TEAE 48 (31.4) 23 (30.3) Ptients with 1 Grde 3 or 4 TEAE 65 (42.5) 34 (44.7) Ptients with TEAEs leding to deth 5 (3.3) 4 (5.3) Ptients with 1 TEAE cusing discontinution, n (%) 13 (8.5) 6 (7.9) TEAEs were blnced between the rms b Progression to AML occurred in 4 ptients (3/153 [2.0%] in the lusptercept rm; 1/76 [1.3%] in the plcebo rm) In lusptercept rm: sepsis (n = 2), multiple orgn dysfunction syndrome, renl filure, nd hemorrhgic shock; in plcebo rm: sepsis, urosepsis, generl physicl helth deteriortion, nd respirtory filure. b The most common grde 3 or 4 TEAEs reported in lusptercept-treted ptients were nemi (6.5% of ptients), fll (4.6%), nd ftigue (4.6%). TEAE, tretment-emergent dverse event.

TEAEs 10% Incidence in Either Arm Plcebo n (%) (n = 153) (n = 76) Ftigue 41 (26.8) 10 (13.2) Dirrhe 34 (22.2) 7 (9.2) Astheni 31 (20.3) 9 (11.8) Nuse 31 (20.3) 6 (7.9) Dizziness 30 (19.6) 4 (5.3) Bck pin 29 (19.0) 5 (6.6) Cough 27 (17.6) 10 (13.2) Edem peripherl 25 (16.3) 13 (17.1) Hedche 24 (15.7) 5 (6.6) Dyspne 23 (15.0) 5 (6.6) Bronchitis 17 (11.1) 1 (1.3) Constiption 17 (11.1) 7 (9.2) Urinry trct infection 17 (11.1) 4 (5.3) Fll 15 (9.8) 9 (11.8) TEAEs 10% incidence in either rm by preferred term

Conclusions In lower-risk, RS-positive MDS, tretment with lusptercept resulted in significntly higher percentge of ptients who chieved RBC-TI, mjor RBC trnsfusion reduction, or hemoglobin increse, compred with plcebo Erythroid responses were durble, with pproximtely 40% of ptients chieving RBC-TI sustined t 12 months of tretment ws generlly well tolerted in this ptient popultion is potentil new therpy for the tretment of ptients with lower-risk, RS-positive MDS with RBC trnsfusion-dependent nemi

Acknowledgements We thnk ll the ptients, fmilies, nd investigtors who prticipted in the study This study ws sponsored by Celgene Corportion, Summit, NJ, USA nd Acceleron Phrm, Cmbridge, MA, USA The uthors received editoril ssistnce from Excerpt Medic (Mirim de Boeck, Emily Poulin, PhD), supported by Celgene Corportion nd Acceleron Phrm The uthors re fully responsible for ll content nd editoril decisions for this presenttion